The rates of P16, RASSF1, and P53 positivity according to IHC did not differ significantly across clinicopathological parameters or between LG-IPMN and A-IPMN dissected regions. This evidence concerns the gene RASSF1 and pancreatic intraductal papillary-mucinous neoplasm.